Program

WEDNESDAY, DECEMBER 5

PROFESSIONAL ADVANCEMENT SESSION
11:15 a.m.-12:45 p.m.
Chairperson: Waun Ki Hong, UT M. D. Anderson Cancer Center, Houston, TX
Supported by the Prevent Cancer Foundation

David S. Alberts, Arizona Cancer Center, Tucson, AZ
Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA
Steven M. Dubinett, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Eva Szabo, National Cancer Institute, Bethesda, MD

EDUCATIONAL SESSIONS I
1:00 p.m.-2:30 p.m.

Carcinogens Cause Cancer: Recent Advances
Chairperson: Stephen S. Hecht, University of Minnesota, Minneapolis, MN

Overview of Human and Tobacco Carcinogens
Stephen S. Hecht
Chemical Carcinogens in the –omics Era
John D. Groopman, Johns Hopkins University, Baltimore, MD
Recent Studies on Aromatic Amines: Human Carcinogens
Mimi Yu, University of Minnesota, Minneapolis, MN

Transdisciplinary Research in Action: Prostate, Cervical, and Tobacco-related Cancer
Chairperson: Caryn Lerman, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Tobacco Use Research: From Cells to Society
Caryn Lerman
Determinants of Disparity in Prostate Cancer Outcomes
Timothy R. Rebbeck, University of Pennsylvania, Philadelphia, PA
Cervical Cancer Disparities in Appalachia, Ohio
Electra D. Paskett, The Ohio State University, Columbus, OH

Tumor Microenvironment
Co-Chairpersons: Adriana Albini, IRCCS Multimedica, Milan, Italy, and Michael B. Sporn, Dartmouth Medical School, Hanover, NH

Introduction
Adriana Albini
The Role of the Tumor Microenvironment in Tumor Progression
Isaac P. Witz, Tel Aviv University, Tel Aviv, Israel
TGF-betas as Modulators of Tumor-Stromal Interactions
Lalage M. Wakefield, National Cancer Institute, Bethesda, MD
Angioprevention: Targeting Angiogenesis and Inflammation in Prevention Strategies
Adriana Albini
Interactions of Triterpenoids and Rexinoids with Stromal Elements in the Microenvironment
Michael B. Sporn

EDUCATIONAL SESSIONS II
2:30 p.m.-4:00 p.m.

Stem Cells
Co-Chairpersons: Michael F. Clarke, Stanford University, Palo Alto, CA, and Timothy C. Wang, Columbia University Medical Center, New York, NY

Self Renewal Pathways in Normal and Cancer Stem Cells
Michael F. Clarke
Inflammation and Cancer Stem Cells
Timothy C. Wang
Brain Tumor Stem Cells in Human and Mouse
Peter B. Dirks, Hospital for Sick Children, Toronto, ON, Canada

Preclinical Models for Prevention
Chairperson: Ming You, Washington University, Saint Louis, MO

Mouse Models of Lung Squamous Cell Carcinomas: Application to Chemoprevention Studies
Ming You
Some Recent Findings of Chemopreventive Agents for the Respiratory Tract Using the Hamster and Mouse Models
Lee W. Wattenberg, University of Minnesota, Minneapolis, MN
Use of a Carcinogen-induced Rat Mammary Tumor Model both to Identify Chemopreventive Agents and to Examine Potential Efficacy Biomarkers
Ronald A. Lubet, National Cancer Institute, Bethesda, MD

Prevention Clinical Trials for the Non-clinician
Chairperson: Scott M. Lippman, UT M. D. Anderson Cancer Center, Houston, TX

Introduction
Scott M. Lippman
From a Glint in the Eye of a Medicinal Chemist to Early-Phase Chemoprevention Trials: Blood, Sweat, and Cheers!
David S. Alberts, University of Arizona, Arizona Cancer Center, Tucson, AZ
Stacking the Odds for Success: Choosing Biomarkers, Endpoints, and Designs for Mid- to Late- Phase Prevention Trials
J. Jack Lee, UT M. D. Anderson Cancer Center, Houston, TX
The Devilish Details of Large-scale Prevention Trials
Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA
Panel discussion

EDUCATIONAL SESSIONS III
4:00 p.m.-5:30 p.m.

Signal Transduction Pathways as Targets for Chemoprevention
Chairperson: Jonathan M. Kurie, UT M. D. Anderson Cancer Center, Houston, TX

Sorting Out Roles for EGF Receptor and Its Ligands in Colonic Neoplasia
Robert J. Coffey, Jr., Vanderbilt University Medical Center, Nashville, TN
Stromal Signaling Pathways as Targets for Prevention
Harold L. Moses, Vanderbilt University, Nashville, TN
Targeting Kinases in Lung Cancer Prevention
Jonathan M. Kurie

Cancer Systems Biology
Chairperson: Gordon B. Mills, UT M. D. Anderson Cancer Center, Houston, TX

Role of Systems Biology in Chemoprevention Drug Identification and Implementation
Gordon B. Mills
An Integromic Approach to Cancer Biomarker Identification
John N. Weinstein, National Cancer Institute, Bethesda, MD
Systems Biology Analysis of Cancer Signaling Networks
Prahlad Ram, UT M. D. Anderson Cancer Center, Houston, TX

Translational Regulation: A Promising Target for Cancer Prevention
Chairperson: Nancy H. Colburn, NCI-Frederick, Frederick, MD

Pdcd4 Targets Translation Initiation to Suppress Tumorigenesis and Invasion
Nancy H. Colburn
Pdcd4, A Colon Cancer Prognostic that is Regulated by a microRNA
Heike Allgayer, University of Heidelberg, Mannheim, Germany
Reprogramming of microRNA Expression by Oncogenes and Tumor Suppressors
Joshua Mendell, Johns Hopkins University, Baltimore, MD

Perception of Cancer Risk: Does It Matter?
Chairperson: Michael E. Stefanek, American Cancer Society, Atlanta, GA

Introduction
Michael E. Stefanek
Affect, Cognition, Superstition: Novel Approaches to Examining Cancer Risk Perceptions in Cancer Prevention and Control
Jennifer L. Hay, Memorial Sloan-Kettering Cancer Center, New York, NY
Psychology of Cancer Risk Perception
William Klein, University of Pittsburgh, Pittsburgh, PA

OPENING KEYNOTE SESSION
6:00 p.m.-8:00 p.m.

Welcome and Remarks
Margaret Foti, CEO, American Association for Cancer Research, and Andrew J. Dannenberg, Program Committee Chairperson

Keynote Address
Inflammation and Cancer Prevention: Is There a Link?
Raymond N. DuBois, UT M. D. Anderson Cancer Center, Houston, TX

Distinguished Lecture on Targets for Cancer Prevention
Nuclear Receptors: Metabolic Engineering and the Dawn of Synthetic Physiology
Ronald M. Evans, The Salk Institute for Biological Studies, La Jolla, CA

OPENING RECEPTION
8:00 p.m.-10:00 p.m.

THURSDAY, DECEMBER 6

MEET-THE-EXPERT SESSIONS I
7:00 a.m.-8:00 a.m.

Tertiary Prevention: Quality Care and Outcomes for Cancer Survivors
Alfred I. Neugut, Columbia University, New York, NY

Prevention Research That Makes a Public Health Difference
Michael J. Thun, American Cancer Society, Atlanta, GA

Pharmacogenetics of NSAIDs and Folate in Colorectal Cancer: Where to Next?
Cornelia M. Ulrich, Fred Hutchinson Cancer Research Center, Seattle, WA

PLENARY SESSION I - PREDICTING CANCER RISK: ADVANCES IN GENETICS, BIOMARKERS, AND BEHAVIORAL SCIENCE
Chairperson: Kenneth Offit, Memorial Sloan-Kettering Cancer Center, New York, NY
8:00 a.m.-10:00 a.m.

Introduction
Kenneth Offit

Genetic Polymorphisms in Breast Cancer Risk and Prevention
James N. Ingle, Mayo Clinic College of Medicine, Rochester, MN

Genome-wide Association Studies in Common Cancers: Identifying Susceptibility Loci in the Genome
Stephen Chanock, National Cancer Institute, Bethesda, MD

Biomarkers for Chemoprevention Studies
Miriam P. Rosin, BC Cancer Research Center, Vancouver, BC, Canada

Behavioral Interventions for Individuals at Increased Risk of Colon Cancer
Sharon Manne, Fox Chase Cancer Center, Philadelphia, PA

CONCURRENT SESSIONS I
10:00 a.m.-12:00 p.m.

Xenobiotic Metabolism and Cancer
Chairperson: Philip Lazarus, Penn State University College of Medicine, Hershey, PA

The UDP-Glucuronosyltransferases and Cancer Susceptibility
Philip Lazarus
Glutathione S-transferases and S-glutathionylation in Cancer
Kenneth D. Tew, Medical University of South Carolina, Charleston, SC
Relationship of PhIP Metabolism and DNA Binding to Cancer Susceptibility
James S. Felton, Lawrence Livermore National Laboratories, Livermore, CA
Tamoxifen Pharmacogenetics: Role in Patient Response and Toxicity
David A. Flockhart, Indiana University, Indianapolis, IN

Epigenomics and Cancer Prevention
Co-Chairpersons: James G. Herman, Johns Hopkins University School of Medicine, and Victoria M. Richon, Merck & Co., Inc., Boston, MA

Changes in DNA Methylation in Cancer and Preinvasive Lesions
James G. Herman
Development of HDAC Inhibitors as Anticancer Agents
Victoria M. Richon
Clinical and Molecular Implications of Epigenetic Alterations in Human Leukemia
Guillermo Garcia-Manero, UT M. D. Anderson Cancer Center, Houston, TX
Histone Modifications in Cancer Biology and Prognosis
Siavash Kurdistani, UCLA School of Medicine, Los Angeles, CA

Science of Policy-related Interventions in Tobacco Control
Chairperson: K. Michael Cummings, Roswell Park Cancer Institute, Buffalo, NY

The International Tobacco Control Policy Evaluation Project: Evaluating the Policies of the Framework Convention on Tobacco Control
Geoffrey T. Fong, University of Waterloo, Waterloo, ON, Canada
What We Know About the Effectiveness of Tobacco Product Regulations: From Smoke-free Policies to Emission Limits to Fire Safe Cigarettes
K. Michael Cummings
What We Know About the Demand Reducing Effects of Taxation Policies and Advertising Bans
Frank J. Chaloupka, University of Illinois, Chicago, IL
What We Know About the Effectiveness of Tobacco Product Labeling Policies: From Warnings to Brand Descriptors
David Hammond, University of Waterloo, Waterloo, ON, Canada
Reflections on the Interface of Science and Policy in Tobacco Control
Robert T. Croyle, National Cancer Institute, Rockville, MD

Hereditary Cancer Syndromes
Chairperson: Steven M. Lipkin, University of California, Irvine, CA

Hereditary Breast Cancer: Beyond BRCA
Kenneth Offit, Memorial Sloan-Kettering Cancer Center, New York, NY
Hereditary Colorectal Cancer
Steven M. Lipkin
The Heritability of Chronic Lymphocytic Leukemia
Albert de la Chapelle, Ohio State University, Columbus, OH

CONCURRENT SESSIONS II
1:00 p.m.-3:00 p.m.

Clinical Prevention Trials
Chairperson: Eva Szabo, National Cancer Institute, Bethesda, MD

Women's Healthy Eating and Living Study: A Phase III Breast Cancer Trial
John P. Pierce, Moores University of California, San Diego Cancer Center, La Jolla, CA
Marked Reduction of the Occurrence of Total and Advanced Adenomas in a Randomized Placebo-controlled Trial of Difluoromethyornitnie Plus Sulindac in Patients with Prior Adenomas
Frank L. Meyskens, Chao Family Comprehensive Cancer Center, Orange, CA
A Phase III Skin Prevention Trial with DFMO
Howard H. Bailey, University of Wisconsin Comprehensive Cancer Center, Madison, WI
Pioglitazone in Oral Leukoplakia: A Phase II Trial
Frank G. Ondrey, University of Minnesota, Minneapolis, MN
Innovative Cancer Prevention Clinical Trial Designs
Eva Szabo, National Cancer Institute, Bethesda, MD

Lung Cancer Screening: Promise and Pitfalls
Chairperson: Christine D. Berg, National Cancer Institute, Rockville, MD

Smoking Cessation Among Lung Cancer Screening Enrollees: Opportunities and Challenges
Jamie S. Ostroff, Memorial Sloan-Kettering Cancer Center, New York, NY
Overdiagnosis: Does It Exist for Lung Cancer?
Peter P. Bach, Memorial Sloan-Kettering Cancer Center, New York, NY
Helical CT Screening for Lung Cancer: Design and Conduct of the National Lung Screening Trial
Christine D. Berg
The Risk of Radiation-induced Cancer from Lung Cancer Screening with Helical CT and Follow-up Diagnostic Evaluations
Amy Berrington de Gonzalez, Johns Hopkins University, Baltimore, MD

New Approaches for Old (and New) Drugs as Cancer Preventive Agents
Chairperson: Andrea U. Decensi, E.O. Ospedali Galliera, Genova, Italy

“Overcoming Resistance” to Old Drugs: The Case of Tamoxifen, Bicalutamide, Budesonide, and Beyond
Andrea U. Decensi
Old Drugs, New Tricks: The Case of Aspirin
John A. Baron, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Taking the One Drug-One Disease Model Forward: Statins and Cancer Risk. A Review of the Evidence
Elizabeth A. Platz, Johns Hopkins University, Baltimore, MD
Insulin Resistance: Influence on Cancer Risk and Cancer Prognosis
Michael N. Pollak, McGill University, Montreal, QC, Canada

Bioactive Food Components and Cancer Prevention
Chairperson: Thomas W. Kensler, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Whole Foods or Phytochemicals? Considerations for Chemoprevention
Jed W. Fahey, Johns Hopkins School of Medicine, Baltimore, MD
Isolation and Evaluation of Natural Product Chemopreventive Agents
John M. Pezzuto, University of Hawaii, Hilo, HI
A Food-based Approach to Prevention of Gastrointestinal Tract Cancers
Gary D. Stoner, Ohio State University, Columbus, OH
Proffered presentations to be announced

PLENARY SESSION II - IMMUNE SYSTEM AS A TARGET FOR PREVENTION
Chairperson: Lisa M. Coussens, UCSF Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA
3:00 p.m.-5:00 p.m.

Psychological Stress, Immune Function, and Cancer Risk
Janice Kiecolt-Glaser, Ohio State University, Columbus, OH

Epigenetic Gene Silencing and Cancer Development: A Mechanistic Link between Inflammation and Human Cancer
William G. Nelson, Johns Hopkins University School of Medicine, Baltimore, MD

Host Immune Response Regulates Cancer Development
Lisa M. Coussens

Aspirin, Other NSAIDs, and Cancer Prevention: Where Are We Now?
Eric Jacobs, American Cancer Society, Atlanta, GA

AACR-PREVENT CANCER FOUNDATION AWARD LECTURE
5:00 p.m.-6:00 p.m.

Breast Cancer Prevention: Learning from the Past, Mentoring the Future
Leslie Bernstein, City of Hope National Medical Center, Duarte, CA

BEHAVIORAL SCIENCE NETWORKING EVENT
Co-Chairpersons: Sharon L. Manne, Fox Chase Cancer Center, Philadelphia, PA, and Michael E. Stefanek, American Cancer Society, Atlanta, GA
6:00 p.m.–7:30 p.m.

MEG SPECIAL SESSION AND RECEPTION
8:00 p.m.-9:30 p.m.

New National Institutes of Health Funding Mechanisms
Robert T. Croyle, National Cancer Institute, Bethesda, MD

POSTER SESSION A
6:00 p.m.-8:00 p.m.

FRIDAY, DECEMBER 7

MEET-THE-EXPERT SESSION II
7:00 a.m.-8:00 a.m.

Prediction of Risk and Outcome: An Integrative Epidemiologic Approach
Margaret R. Spitz, UT M. D. Anderson Cancer Center, Houston, TX

Models of Esophageal Cancer: Implications for Prevention and Therapy
Anil K. Rustgi, University of Pennsylvania, Philadelphia, PA

Who Gets Genetic Testing and Why?
Suzanne M. Miller, Fox Chase Cancer Center, Philadelphia, PA

PLENARY SESSION III - OBESITY, METABOLISM, AND CANCER
Chairperson: Craig B. Thompson, University of Pennsylvania, Philadelphia, PA
8:00 a.m.-10:00 a.m.

Mutations That Fuel Cancer Cell Growth
Craig B. Thompson

Obesity and Cancer: Trends, Targets, and Transgenics
Steven D. Hursting, University of Texas, Austin, TX

Molecular Links Between Metabolic Pathways and Cancer in Obesity
Geoffrey D. Girnun, University of Maryland, Greenebaum Cancer Center, Baltimore, MD

The Role of Noncarbohydrate Substrates in Cancer Metabolism
Tak W. Mak, The Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

CONCURRENT SESSIONS III
10:00 a.m.-12:00 p.m.

Pathway Discovery and Molecular Signatures for Cancer Risk
Co-Chairpersons: Thomas A. Sellers, H. Lee Moffitt Cancer Center, Tampa, FL, and Peter G. Shields, Georgetown University Medical Center, Washington, DC

Identifying Gene Expression Profiles from Tobacco and Nicotine Exposure
Peter G. Shields
Pathway Approaches to Ovarian Cancer Risk Discovery
Thomas Sellers
Unraveling the Genetic Etiology of Mammographic Breast Density
Celine M. Vachon, Mayo Clinic College of Medicine, Rochester, MN
CpG Island Methylator Phenotype and Colorectal Cancer
Martha L. Slattery, University of Utah, Salt Lake City, UT

Helicobacter pylori and Gastric Cancer
Co-Chairpersons: Pelayo Correa, Vanderbilt University, Nashville, TN, and James G. Fox, Massachusetts Institute of Technology, Cambridge, MA

The Prevention of Gastric Cancer
Pelayo Correa
H. pylori Eradication in the Prevention of Gastric Cancer
Benjamin C. Y. Wong, University of Hong Kong, Pokfulam, Hong Kong
Role of Bone Marrow Derived Cells in Gastric Cancer
JeanMarie Houghton, University of Massachusetts Medical School, Worcester, MA
Pathogenesis of Gastric Cancer: Lessons from Mouse Models
James G. Fox

Bioactive Lipids and Cancer Prevention
Co-Chairpersons: Makoto Mark Taketo, Kyoto University, Kyoto, Japan and Timothy Hla, University of Connecticut Health Center, Farmington, CT

G Protein-coupled Receptors and Cancer: Emerging Paradigms
J. Silvio Gutkind, National Institutes of Health, Bethesda, MD
Sphingolipid Metabolism and Signaling in Cancer and Angiogenesis
Timothy Hla
PGE2 and Wnt in Gastric Cancer Models
Makoto Mark Taketo
12-Lipoxygenase in Carcinogenesis
Kenneth V. Honn, Wayne State University, Detroit, MI

Application of Mass Spectrometry to Detection and Prevention
Co-Chairpersons: Ian A. Blair, University of Pennsylvania, Philadelphia, PA, and Elise C. Kohn, National Cancer Institute, Bethesda, MD

Analysis of Endogenous DNA Adducts by Mass Spectrometry
Ian A. Blair
Analysis of DNA Lesion Bypass by Mass Spectrometry
Carmelo Rizzo, Vanderbilt University, Nashville, TN
Tissue Proteomics: Applications of Mass Spectrometry for Discovery and Validation of Biomarkers for Cancer Early Detection
Thomas P. Conrads, University of Pittsburgh, Pittsburgh, PA
Optimization and Application of Serum Mass Spectrometry for Detection and Prevention
Elise C. Kohn

CONCURRENT SESSIONS IV
1:00 p.m.-3:00 p.m.

Progression and Prevention of Barrett's Esophagus
Chairperson: Carlo C. Maley, The Wistar Institute, University of Pennsylvania, Philadelphia, PA

Clonal Evolution in Barrett’s Esophagus
Carlo C. Maley
The Origin and Prevention of Barrett’s Esophagus
Rebecca Fitzgerald, Hutchison, MRC Research Center, Cambridge, England
The Genetics and Epigenetics of Barrett's Esophagus and Esophageal Adenocarcinoma
Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA
Endoscopic Applications of Chemoprevention in Barrett's Esophagus
Kenneth K. Wang, Mayo Medical Center, Rochester, MN

Novel Targets for Prevention of Breast Cancer
Chairperson: Powel H. Brown, Baylor College of Medicine, Houston, TX

Polarity Pathways: New Strategies to Target Precancer
Senthil K. Muthuswamy, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Novel Kinases and P38 as a Target for Treatment and Prevention
Powel H. Brown
HDAC Inhibitors for Treatment and Prevention
Nancy E. Davidson, Johns Hopkins Oncology Center, Baltimore, MD

Melanoma and Non-melanoma Skin Cancer
Chairperson: Frank L. Meyskens, UC Irvine, Chao Family Comprehensive Cancer Center, Orange, CA

New Approaches to the Prevention of Cutaneous Melanoma by Regulation of Redox
Frank L. Meyskens
Regulation of Cyclic AMP as a Prevention Strategy for Melanoma
John D’Orazio, University of Kentucky, Lexington, KY
Molecular Mechanisms of UV-induced Non-melanoma Skin Cancer and Preventive Approaches
Zigang Dong, University of Minnesota, Austin, MN
Non-melanoma Skin Cancer Chemoprevention in Organ Transplant Recipients
Howard H. Bailey, University of Wisconsin Comprehensive Cancer Center, Madison, WI

Colon Cancer Prevention: Current Clinical Applications
Chairperson: Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA

Predicting Patient Adenoma Risk for Assigning Follow-up Management
Ann G. Zauber, Memorial Sloan-Kettering Cancer Center, New York, NY
The Methods of Recognizing and Assigning Familial Risk
Randall Burt, University of Utah School of Medicine, Salt Lake City, UT
The Role of Colonoscopy and Polypectomy in the Prevention of Colorectal Cancer
Sidney J. Winawer, Memorial Sloan-Kettering Cancer Center, New York, NY
Chemoprevention for Colorectal Cancer
Monica M. Bertagnolli

Biological versus Social Constructs of Health Disparities
Chairperson: Olufunmilayo I. Olopade, University of Chicago Medical Center, Chicago, IL

Moving Toward the Elimination of Cancer Health Disparities
Judith S. Kaur, Mayo Clinic College of Medicine, Rochester, MN
Genetics and Prostate Cancer Risk
Rick A. Kittles, University of Chicago, Chicago, IL
Addressing Cancer Health Disparities in Hispanics and Native Americans in the Southwest
Maria Elena Martinez, Arizona Cancer Center, Tucson, AZ
Developing Novel Approaches to Breast Cancer: Are We There Yet?
Olufunmilayo I. Olopade

PLENARY SESSION IV - IMAGING PRE-MALIGNANT DISEASE AND CANCER
Co-Chairpersons: Gary J. Kelloff, National Cancer Institute, Rockville, MD, and Mitchell D. Schnall, University of Pennsylvania, Philadelphia, PA
3:00 p.m.-5:00 p.m.

Overview of Imaging and Its Promise for Detection, Diagnosis, and Therapy Monitoring of Precancer
Gary J. Kelloff

Targeted Imaging of Cyclooxygenase-2
Lawrence J. Marnett, Vanderbilt University, Nashville, TN

Opportunities in Imaging for Prevention of Lung Cancer
Stephen Lam, University of British Columbia, Vancouver, BC, Canada

Role of Imaging in Personalized Surveillance and Response Monitoring in Breast and Other Cancers
Mitchell D. Schnall

CONTROVERSY SESSIONS
5:00 p.m.-6:00 p.m.

Smokeless Tobacco: A Substitute for Smoking?
Moderator: Stephen S. Hecht, University of Minnesota, Minneapolis, MN

Introduction
Stephen S. Hecht
In Favor of Smokeless Tobacco?
David Levy, Pacific Institute for Research and Evaluation, Calverton, MD
Why Smokeless Tobacco Is an Inappropriate Public Health Strategy for Reducing Societal Harm from Cigarette Smoking in the United States
Scott L. Tomar, University of Florida, Gainesville, FL

SERMS versus Aromatase Inhibitors
Moderator: Powel H. Brown, Baylor College of Medicine, Houston, TX

Introduction
Powel H. Brown
Reduction of Breast Cancer Risk Using SERMs
Victor G. Vogel, University of Pittsburgh Magee Women’s Hospital, Pittsburgh, PA
Prevention of Breast Cancer Using Aromatase Inhibitors
Jack Cuzick, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, London, England

SPECIAL SESSION
5:00 p.m.-6:00 p.m.

Introduction
Martin Wiseman, World Cancer Research Fund International, London, United Kingdom

Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective
Supported by the World Cancer Research Fund International and the American Institute for Cancer Research

Tim E. Byers, University of Colorado Health Sciences Center, Denver, CO

POSTER SESSION B
5:00 p.m.-7:00 p.m.

SATURDAY, DECEMBER 8

PLENARY SESSION V - UNDERSTANDING AND PREVENTING CANCERS DUE TO MICROBES
Co-Chairpersons: Martin J. Blaser, New York University School of Medicine, New York, NY, and Silvia Franceschi, International Agency for Research on Cancer, Lyon, France
8:00 a.m.-10:00 a.m.

Burden of Cancer Attributable to Infection
Silvia Franceschi

Viral and Host Factors and Risk of Hepatocellular Carcinoma
Ming-Whei Yu, National Taiwan University, Tapei, Taiwan

Linking Helicobacter pylori Regulation of Gastric Physiology to Cancer Development
Martin J. Blaser

A Shot in the Arm? Cervical Cancer Prevention in the HPV Vaccine Era
Philip Castle, National Cancer Institute, Rockville, MD

CONCURRENT SESSIONS V
10:00 a.m.-12:00 p.m.

Issues in the Use of Intermediate Endpoints
Co-Chairpersons: Ernest T. Hawk, National Cancer Institute, Bethesda, MD, and Ronald A. Lubet, National Cancer Institute, Bethesda, MD

Introduction
Ronald A. Lubet
Proteomics Analysis of Chemically Induced Rat Bladder Tumors
R. Reid Townsend, Washington University, St. Louis, MO
Effects of Various Cancer Preventive Agents on Proliferation and Apoptosis in a Rat Mammary Cancer Model and Correlations with Preventive/Therapeutic Efficacy
Konstantin T. Christov, University of Illinois, Chicago, IL
The Facts, Fiction, and Future of Intermediate Endpoints in Clinical Prevention
Ernest T. Hawk
Effects of Combination Chemoprevention on Markers of Cell Turnover and Agent Action in Colorectal Mucosal Tissue from Patients in a Phase III Trial of Difluoromethylornithine and Sulindac for Prevention of Colon Polyp Recurrence
Eugene Gerner, Arizona Cancer Center, Tucson, AZ

Basic and Translational Advances in Lung Carcinogenesis and Chemoprevention
Co-Chairpersons: Steven M. Dubinett, UCLA School of Medicine, Los Angeles, CA, and Fadlo R. Khuri, Emory University School of Medicine, Atlanta, GA

Examining the Role of Stem Cell Biology in Lung Cancer
Carla F. Kim, Children’s Hospital Boston, Boston, MA
Field Effect in Lung Carcinogenesis
Ignacio Wistuba, UT M. D. Anderson Cancer Center, Houston, TX
Inflammation in Lung Carcinogenesis and Chemoprevention
Steven M. Dubinett
Natural Product-based Drug Discovery for Lung Cancer Prevention and Therapy
Haian Fu, Emory University, Atlanta, GA

Prostate Cancer Prevention: Translating from the Bench to the Bedside to the Nation
Chairperson: Ian M. Thompson, University of Texas Health Science Center, San Antonio, TX

Molecular Biology of Chemoprevention
Ashraful Hoque, UT M. D. Anderson Cancer Center, Houston, TX
Prevention with 5-Alpha Reductase Inhibitors
Ian M. Thompson
Genetic Susceptibility and Inflammation: Implications for Prevention of Prostate Cancer
Eric A. Klein, Cleveland Clinic, Cleveland, OH
Taking Prevention to the Public: Challenges and Solutions for Prevention as a Public Health Initiative
Leslie G. Ford, National Cancer Institute, Bethesda, MD

Informed Decision-Making for Cancer Screening and Prevention
Chairperson: Peter A. Ubel, University of Michigan, Ann Arbor, MI

Deciding When a Decision is a "Good" Decision
Peter Ubel
Primary Prevention with Tamoxifen or Raloxifene: Results from an Experimental Decision Aid
Angela Fagerlin, University of Michigan, Ann Arbor, MI
Whom You See Is What You Get: Understanding Optimal Cancer Decisions in a World of Constrained Choice
Katrina Armstrong, University of Pennsylvania, Philadelphia, PA
Cancer Prevention Online? Decision Making in the Context of Direct to Consumer Cancer Genetics
Stacy W. Gray, University of Pennsylvania, Philadelphia, PA

DEPARTURE

Top of page